Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438487 · ClinicalTrials.gov registry record
Flucelvax (TIVc or QIVc) Pregnancy Registry
A clinical trial, sponsored by Seqirus.
- Completed
- Registry status
- 692
- Enrollment target
NCT03438487: Completed study, sponsored by Seqirus.
NCT03438487 is a clinical trial that has completed, run by Seqirus. The registered enrollment target is 692 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03438487 has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- 692 participants
- Enrollment target
Study Summary
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Primary Outcome
Number of cases for pregnancy outcomes will be reported as one of the following: live birth, stillbirth, spontaneous abortion and elective termination
Interventions
- BIOLOGICAL Flucelvax Trivalent Influenza Vaccine
- BIOLOGICAL Flucelvax Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-12-31 |
What the finished NCT03438487 record still lists
NCT03438487 is an observational study that tracks outcomes without assigning an intervention. The registered 692 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Flucelvax Trivalent Influenza Vaccine is the first listed.
NCT03438487 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03438487 about?
NCT03438487 is a clinical study titled "Flucelvax (TIVc or QIVc) Pregnancy Registry". The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
What is the current status of trial NCT03438487?
This trial is currently completed. The enrollment target is 692 participants. The study started on 2017-09-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03438487?
The interventions under investigation include: Flucelvax Trivalent Influenza Vaccine (BIOLOGICAL), Flucelvax Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03438487?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI